Dr Reddy stock at INR 1,229.40, 13.1 percent below its high

Published on 10/12/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The P/E ratio is 30.96 versus Sun Pharma at 34.91. Dr Reddy stock was last at INR 1,229.40 on October 12, 2026, below INR 1,414.90.

Key points in brief

Dr Reddy stock was last at INR 1,229.40 on October 12, 2026, with a 52-week range of INR 1,101.00 to INR 1,414.90.
The stock's P/E ratio was 30.96, compared with 34.91 for Sun Pharmaceutical and 31.45 for Cipla.
Dr. Reddy's Laboratories is scheduled to announce results for the quarter and six months ended September 30, 2026, on October 23, 2026.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

At INR 1,229.40, Dr Reddy stock was last quoted on October 12, 2026, at 3:29 p.m. IST on the NSE. The price stands 13.1 percent below its 52-week high of INR 1,414.90 and 11.66 percent above its 52-week low of INR 1,101.00.

Valuation remains measurable

The latest quote puts Dr. Reddy's Laboratories at a market capitalization of INR 1.0 trillion and a P/E ratio of 30.96. Its dividend yield is 0.01 percent, while trading volume reached 1,813,491 shares against an average volume of 1,939,303.

The range places the stock in the lower part of its annual band, with a 13.1 percent gap to the high and a 11.66 percent premium to the low. These two reference points give investors a clearer frame than the absolute share price alone.

Comparison with peers

Dr Reddy (NSE, INR): , P/E 30.96, market capitalization INR 1.0 trillion

Sun Pharmaceutical (NSE, INR): unchanged, P/E 34.91, market capitalization INR 4.2 trillion

Cipla (NSE, INR): plus 0.79 percent, P/E 31.45, market capitalization INR 1.1 trillion

Results date sets the next marker

StockTitan reports that Dr. Reddy's Laboratories will announce results for the quarter and six months ended September 30, 2026, on October 23, 2026, after a board meeting. The company scheduled its earnings call for 10:00 a.m. ET on the same date.

The upcoming report will give the market a fresh comparison with the first quarter of fiscal 2027, when revenue was INR 80.71 billion and net income was INR 4.44 billion. Those figures are already reflected in the latest quarterly reporting period, so the October release will be the next substantive operating checkpoint.

Price stays below the annual high

Dr Reddy was last at INR 1,229.40 on the NSE on October 12, 2026 at 3:29 p.m. IST. The stock's valuation remains below Sun Pharmaceutical's P/E of 34.91 and close to Cipla's P/E of 31.45.

Market context: Market report BSE Sensex.

More news and analyses on Dr Reddy stock